title: A report from the 167th American Psychiatric Association Annual Meeting (May 3-7 - New York, U.S.A.).
abstract: Sharing space with a fashion fair, the American Psychiatric Association's Annual Meeting took place at the Javits Center on the West side of Manhattan where psychiatrists and psychiatry-focused neuroscientists met to discuss the latest advances in antipsychotic, antidepressant and related therapies. Mixing psychiatry with fashion was a psychedelic experience, but the meeting was too busy to give more than a passing glimpse to screens showing the newest trends in fashion. Revival of old styles? That in a sense also happened in psychiatry, with experts defending the current place of lithium in therapeutics. Newest, youngest look? That was also true for psychiatry, with new investigational therapeutics challenging the place of older treatment approaches because of improved efficacy, better safety and tolerability, or easier administration. What about these patchwork trends? This again was met in psychiatry, with combination therapies aimed at a more comprehensive control of underlying processes in diseases such as schizophrenia. And these nice complements, or a few highlights? Psychiatric therapies also include augmentation strategies, which were discussed during this year's meeting along with examples of the previously mentioned approaches that are included in the following report.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D002491:Central Nervous System Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D009519:New York City
chemical_list: D002491:Central Nervous System Agents
keywords: Anxiety; Bipolar disorder; Major depression; Psychiatric disorders